Description
Retatrutide Powder is a synthetic modified peptide developed from a GIP-related backbone. It contains 39 amino acid residues, including non-natural amino acids and a C20 fatty diacid side chain. The material is produced through peptide synthesis, followed by purification and powder preparation for laboratory use.
This peptide is studied for its activity at GIPR, GLP-1R, and GCGR. These three targets do not show identical potency, so the molecule should not be understood as a simple blend of three peptides. Its modified structure, side-chain attachment, and complete molecular mass are important parts of product identification.
Shaanxi Medibridge Biotech Co., Ltd. supplies this material as research-grade powder or customized vial filling. Each batch can be supported with HPLC purity data, LC-MS identity testing, COA, and agreed packaging details. The product is supplied for research use only.
COA
Built On A GIP Backbone
The starting point comes from a GIP-related sequence, but the finished structure is not identical to native GIP. During development, certain positions in the chain were adjusted, resulting in a peptide made up of 39 amino acid residues.
Some of these positions use non-natural amino acids rather than standard residues. The chain also carries a lipid-linked side group at a defined lysine site. These changes form part of the molecular identity, not just an added formulation feature.
For this reason, the sequence alone does not fully describe the material. The modified residues, attachment position, terminal form, and complete molecular mass all need to match the stated structure.
This backbone also explains why the material should be reviewed as one engineered peptide rather than as a mixture of separate receptor ligands.
Where The Structure Changes
Non-Natural Residues
The chain includes Aib residues at defined positions, together with an alpha-methyl leucine substitution. These are not ordinary sequence details. They change the composition of the peptide and need to be included when the theoretical mass and final identity are checked.
Lipid-Linked Side Chain
A C20 fatty diacid is linked to a defined lysine residue through a short spacer. This group is built into the molecule itself rather than added later. It shows up clearly in molecular weight calculations, shifts the HPLC profile, and is reflected in the mass spectrum.
Terminal Form And Full Identity
The C-terminal form also needs to match the stated structure. A correct sequence is only one part of the review. The modified residues, lipid attachment, terminal form, and complete molecular mass should all point to the same molecular identity.
Three Targets, Not Equal Activity
Retatrutide Powder shows activity at GIPR, GLP-1R, and GCGR, but the three responses are not identical. In published cell-based assays, GIPR activity is the strongest, GLP-1R follows, and GCGR activity is present at a lower potency.
GIPR Leads The Profile
The GIP receptor is the most responsive of the three in reported in vitro testing. This makes the GIP-related backbone more than a structural starting point; it remains a major part of the final receptor profile.
GLP-1R Remains Active
GLP-1R activity is clearly retained, although it is not equal to the GIPR response. Its presence helps distinguish the molecule from a single-receptor GIP analogue.
GCGR Adds A Third Axis
GCGR activity rounds out the three-target profile. In most assay setups it appears at a lower potency, but it is still part of the intended design rather than a background effect.
Potency values can shift depending on how the assay is run, so these comparisons are best read as relative in vitro data, not as direct indicators of research outcomes.
Purity Alone Is Not Enough
Purity Alone Is Not Enough
A high HPLC value shows the proportion of the main chromatographic peak under a defined method. It does not confirm the full sequence, lipid attachment, or intact molecular mass.
HPLC Main Peak
HPLC can reveal truncated chains, incomplete products, and other related peaks. The result should be read together with the test method, since column type, gradient, wavelength, and sample concentration can affect separation.
Intact Mass
LC-MS should match the complete modified structure, including the non-natural residues, linker, C20 fatty diacid group, and terminal form. A mass result based only on the peptide chain is incomplete.
Batch Composition
HPLC purity is not the same as peptide content. Water, counterions, and residual processing components may still be present in the powder. Peptide content, water content, residual solvents, and counterion information should therefore be reviewed alongside purity and identity data.
What A Batch Document Should Show
What A Batch Document Should Show
A useful batch document should make the material easy to identify, compare, and trace. It should show more than a single purity value.
Identity Records
The document should include the batch number, product form, stated molecular weight, and LC-MS result. The declared structure and the measured mass need to match the same material.
Composition Data
HPLC purity, peptide content, water content, residual solvents, and counterion information should be listed separately where applicable. These values describe different parts of the powder and should not be combined into one headline figure.
Batch Traceability
Testing date, specification, storage condition, packaging details, and release conclusion should be easy to find. For larger projects, the same document format should be kept across batches so later comparisons remain straightforward.
From Powder To Project Supply
Research Powder Form
The material can be supplied as bulk powder or filled into vials. Bulk form is usually selected for formulation work, analytical studies, or internal repacking. Vial filling is more suitable when the project needs fixed quantities and fewer repeated openings.
Packaging By Project
Fill weight, vial size, label format, and the number of units can be discussed before production. Small packs may be useful for separate test stages, while larger packs can reduce unnecessary packaging for continuous laboratory work.
Batch Planning
Projects that require the same batch should confirm the total quantity and delivery schedule in advance. Sample evaluation can be arranged before a larger order, and part of the batch may be reserved when later testing or repeat work is expected.
The supplied form remains a research material. It is not a prepared solution or a finished pharmaceutical product.
Clear Research Scope
Clear Research Scope
The supplied powder is intended for controlled laboratory work, including analytical testing, receptor studies, and formulation evaluation. It is provided as a research raw material rather than a dosage form or finished medicine. Published human-study data refer to an investigational molecule used under formal clinical protocols and should not be treated as a description of the material supplied on this page.
FAQ
Frequently Asked Questions
Is this a blend of three peptides?
+
-
No. It is one modified 39-residue peptide with activity at three different receptors.
Why is LC-MS important for this material?
+
-
LC-MS helps confirm whether the measured mass matches the complete modified molecule.
Can the material be supplied as bulk powder?
+
-
Yes. Bulk powder and custom vial filling are both available for research projects.
Is the supplied powder a finished medicine?
+
-
No. It is a research raw material and is not supplied as a dosage form or finished pharmaceutical product.
How can I request a Retatrutide Powder quotation?
+
-
Send the required quantity, powder or vial format, fill weight, and document requirements for review.
Hot Tags: retatrutide powder, China retatrutide powder manufacturers, suppliers, factory, Dsip Peptide Powder, Hcg Powder, Ipamorelin Powder, Survodutide Peptide, tesamorelin assay tested powder, tesamorelin formulation ingredient
